摘要
目的评估齐拉西酮在巩固期改善精神分裂症患者临床症状的同时对于患者体重指数、腰围的影响。方法选择197例精神分裂症患者,起始5周采用奥氮平联合齐拉西酮治疗,5周后随机分为奥氮平联合齐拉西酮组98例(联用组),单用齐拉西酮组99例(单药组),所有入组患者在治疗前和治疗后1、5、7、9、12周使用阳性症状与阴性症状量表(PANSS)、临床疗效总评量表(CGI)、不良反应症状量表(TESS)评定入组患者疗效与不良反应,同时测定所有患者体重指数、腰围。结果治疗后1、5、7、9、12周PANSS、CGI评定,2组间同时点PANSS、CGI评分比较差异无统计学意义(P>0.05)。在治疗后5周末,单药组体重指数、腰围与治疗前比较差异无统计学意义(P>0.05);治疗12周末时,与治疗前比较差异有统计学意义(P<0.01)。在治疗后5周末,联用组体重指数、腰围与治疗前比较差异有统计学意义(P<0.05或P<0.01);治疗12周末时,与治疗前比较差异有统计学意义(P<0.01)。结论齐拉西酮联合奥氮平治疗精神分裂症5周后,单用齐拉西酮临床疗效与联合使用疗效相当,单用齐拉西酮对患者体重指数、腰围影响小,适合长期维持治疗。
Objective To observe the change of body mass index( BMI) and waistline of schizophrenia patients in maintenance therapy with ziprasidone. Methods 197 cases of schizophrenia were selected into the trial. All the patients were administered with ziprasidone and olanzapine within the first 5 weeks. After the 5 weeks,all patients were randomly divided into combination group( 98 cases administered with ziprasidone and olanzapine) and single group( 99 cases administered only with ziprasidone). The curative efficacy and adverse effect were assessed by Positive and Negative Syndrome Scale( PANSS),Clinical Global Impression Scale( CGI),Treatment Emergent Symptom Scale( TESS) before the treatment and on the 1st,5th,7th,9th,12 th weekend after the treatment. BMI and waistline of all patients were measured at the same time. Results There was no statistical difference in scores of PANSS and CGI between the two groups at the 1st,5th,7th,9th,12 th weekend after the treatment( P > 0. 05). The BMI and waistline of patients in single group hadn't statistical difference as compared with pre-treatment at the 5th week( P > 0. 05),but both BMI and waistline were much lower than those of pre-treatment at the 12 th week( P < 0. 01). Both BMI and waistline of patients in the combination group had statistical difference as compared with pre-treatment at the 5th week( P < 0. 05 or P < 0. 01) and 12 th week( P < 0. 01).Conclusion After 5-week therapy with ziprasidone and olanzapine,the efficacy of maintenance therapy by single ziprasidone is almost amount to that by combination of ziprasidone and olanzapine,but the single ziprasidone is more apt to longterm maintenance treatment for its small effect on patients' BMI and waistline.
出处
《中华全科医学》
2015年第10期1594-1596,1616,共4页
Chinese Journal of General Practice
基金
浙江省桐乡市课题(201403122)
浙江省嘉兴市科技计划项目(2014AY21064)
